We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) to Report Q2 Earnings: What's in the Offing?
Read MoreHide Full Article
Agilent Technologies (A - Free Report) is set to report second-quarter fiscal 2021 results on May 25.
For the fiscal second quarter, the company expects revenues of $1.37-$1.39 billion, indicating core growth of 7-9% from the year-ago reported figure. The Zacks Consensus Estimate for revenues is pegged at $1.39 billion, implying year-over-year growth of 12.1%.
Earnings per share are expected to be 78-80 cents. The Zacks Consensus Estimate for earnings is pegged at 82 cents per share,which indicates growth of 15.5% from the year-ago reported figure.
The company surpassed the Zacks Consensus Estimate in all the trailing four quarters, the earnings surprise being 16.85%, on average.
Agilent’s expanding product portfolio and strong end-market momentum must have been the key growth driver in the to-be-reported quarter.
Moreover, the company’s increasing investments in promising markets, such as biopharma, are anticipated to have served as tailwinds in the quarter under review.
Further, in the fiscal second quarter, Agilent completed the buyout of Resolution Bioscience, which bolstered its capabilities in next-generation sequencing-based cancer diagnostics. This is expected tohave contributed well to the performance of the company’s diagnostics and genomics business.
Also, the acquisition is expected to have driven the company’s momentum across biopharma and clinical diagnostics customers.
Apart from this, the company introduced 8697 Headspace Sampler, which is expected to have added strength to its instrument intelligence capabilities. This has likely aided its performance in the pharmaceutical market and has benefited the Gas Phase Separations division in the fiscal second quarter.
Coming to segments, the company’s Life Sciences & Applied Markets Group is expected to have performed well in the quarter to be reported, owing togrowth in food and pharma markets. Also, strength in cell analysis, liquid chromatography and mass spectrometry is likely to have contributed well.
Further, Agilent’s Diagnostics and Genomics Group is expected to have performed well in the to-be-reported quarter, driven by growth in pharma and strength in genomics.
Also, Cross Lab Group of the company is expected to have benefited from an improving lab operating environment.
However, COVID-led disruptions and currency headwinds are expected to have been overhangs. Also, macro weakness in some regions and higher expenses are expected to get reflected in the company’s fiscal second-quarter results.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Agilent this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Agilent has an Earnings ESP of 0.00% and a Zacks Rank #3.
Stocks to Consider
Here are some stocks to consider as our model shows that these have the right combination of elements to beat on earnings this season.
Pure Storage (PSTG - Free Report) currently has an Earnings ESP of +10.81% and a Zacks Rank of 3.
NVIDIA (NVDA - Free Report) has an Earnings ESP of +1.96% and a Zacks Rank #2 at present.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Agilent (A) to Report Q2 Earnings: What's in the Offing?
Agilent Technologies (A - Free Report) is set to report second-quarter fiscal 2021 results on May 25.
For the fiscal second quarter, the company expects revenues of $1.37-$1.39 billion, indicating core growth of 7-9% from the year-ago reported figure. The Zacks Consensus Estimate for revenues is pegged at $1.39 billion, implying year-over-year growth of 12.1%.
Earnings per share are expected to be 78-80 cents. The Zacks Consensus Estimate for earnings is pegged at 82 cents per share,which indicates growth of 15.5% from the year-ago reported figure.
The company surpassed the Zacks Consensus Estimate in all the trailing four quarters, the earnings surprise being 16.85%, on average.
Agilent Technologies, Inc. Price and EPS Surprise
Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote
Factors to Consider
Agilent’s expanding product portfolio and strong end-market momentum must have been the key growth driver in the to-be-reported quarter.
Moreover, the company’s increasing investments in promising markets, such as biopharma, are anticipated to have served as tailwinds in the quarter under review.
Further, in the fiscal second quarter, Agilent completed the buyout of Resolution Bioscience, which bolstered its capabilities in next-generation sequencing-based cancer diagnostics. This is expected tohave contributed well to the performance of the company’s diagnostics and genomics business.
Also, the acquisition is expected to have driven the company’s momentum across biopharma and clinical diagnostics customers.
Apart from this, the company introduced 8697 Headspace Sampler, which is expected to have added strength to its instrument intelligence capabilities. This has likely aided its performance in the pharmaceutical market and has benefited the Gas Phase Separations division in the fiscal second quarter.
Coming to segments, the company’s Life Sciences & Applied Markets Group is expected to have performed well in the quarter to be reported, owing togrowth in food and pharma markets. Also, strength in cell analysis, liquid chromatography and mass spectrometry is likely to have contributed well.
Further, Agilent’s Diagnostics and Genomics Group is expected to have performed well in the to-be-reported quarter, driven by growth in pharma and strength in genomics.
Also, Cross Lab Group of the company is expected to have benefited from an improving lab operating environment.
However, COVID-led disruptions and currency headwinds are expected to have been overhangs. Also, macro weakness in some regions and higher expenses are expected to get reflected in the company’s fiscal second-quarter results.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Agilent this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Agilent has an Earnings ESP of 0.00% and a Zacks Rank #3.
Stocks to Consider
Here are some stocks to consider as our model shows that these have the right combination of elements to beat on earnings this season.
Digital Turbine (APPS - Free Report) has an Earnings ESP of +6.98% and it sports a Zacks Rank of 1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pure Storage (PSTG - Free Report) currently has an Earnings ESP of +10.81% and a Zacks Rank of 3.
NVIDIA (NVDA - Free Report) has an Earnings ESP of +1.96% and a Zacks Rank #2 at present.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>